Insulin Market in the US and Europe 2016-2020

  • ID: 3721898
  • Report
  • Region: Europe, United States
  • 95 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Adocia
  • Boehringer Ingelheim
  • Exsulin
  • Macrogenics
  • NGM Biopharmaceuticals
  • Pfizer
  • MORE
About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

The analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:
- US
- Europe

The report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Sanofi
- Novo Nordisk
- Eli Lilly

Other prominent vendors
- Adocia
- Biocon
- Biodel
- Biogenomics
- Boehringer Ingelheim
- Dance Biopharm
- Diasome Pharmaceuticals
- Exsulin
- Generex
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- MannKind
- Macrogenics
- Merck
- Melior Pharmaceuticals
- Metabolic Solutions Development Company
- NGM Biopharmaceuticals
- NuSirt Biopharma
- Oramed Pharmceuticals
- PhaseBio Pharmaceuticals
- Pfizer
- Thermalin Diabetes
- Tolerion
- VeroScience
- vTv Therapeutics
- Wockhardt
- XOMA

Market drivers
- Advances in insulin delivery technology
- For a full, detailed list, view the full report

Market challenges
- Complexity of insulin production
- For a full, detailed list, view the full report

Market trends
- Increasing price of insulin drugs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adocia
  • Boehringer Ingelheim
  • Exsulin
  • Macrogenics
  • NGM Biopharmaceuticals
  • Pfizer
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Assumptions:
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Key buying criteria
PART 05: Major branded drug profiles
  • Actrapid
  • Apidra
  • Humalog
  • Insuman
  • Lantus
  • Levemir
  • NovoMix
  • NovoRapid
  • Toujeo
  • Tresiba
PART 06: Insulin: An overview
  • History of insulin
  • Epidemiology
  • Reimbursement scenario
  • Patent scenario for approved products
PART 07: Pipeline portfolio
  • Xultophy (NN9068)
  • Faster-acting insulin as
PART (NN1218)
  • SAR342434
  • LY2605541
  • MK-1293
  • Oral-Lyn
PART 08: Oral insulin therapies
  • Upcoming vendors for oral insulin therapies
  • Oramed Pharmaceuticals
  • Generex Biotechnology
PART 09: Market landscape
  • Global insulin market
  • Insulin market in US and Europe
  • Market size and forecast
  • Five forces analysis
PART 10: Market segmentation by drug class
  • Fast-acting insulin
  • Intermediate-acting insulin
  • Long-acting insulin
PART 11: Market segmentation by application
  • Type 1 diabetes
  • Type 2 diabetes
PART 12: Market segmentation by insulin delivery technologies
  • Injectable insulin
  • Oral insulin
  • Inhaled insulin
  • Other emerging insulin delivery technologies
  • Insulin pumps
PART 13: Geographical segmentation
  • Insulin market in US
  • Insulin market in Europe
PART 14: Market drivers
  • Advances in insulin delivery technology
  • Unmet medical needs
  • Increase in prevalence of diabetes and obesity
  • Increase in awareness of diabetes
PART 15: Impact of drivers

PART 16: Market challenges
  • Complexity of insulin production
  • Poor storage condition and distribution policies
  • Stringent regulatory environment
  • Inconvenient ROA
PART 17: Impact of drivers and challenges

PART 18: Market trends
  • Increase in R&D for novel mechanisms
  • Increase in academia-industry collaborations for drug development
  • Increasing price of insulin drugs
  • Intense competition among present and upcoming vendors
PART 19: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Other prominent vendors
PART 20: Appendix
  • List of abbreviations
PART 21: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for insulin
Exhibit 03: History of insulin development
Exhibit 04: Incidence of diabetes among ethnic groups in US 2014
Exhibit 05: Diagnosed and undiagnosed diabetes in US by gender 2012
Exhibit 06: Diagnosed and undiagnosed diabetes in people aged 20 years or older in US 2012
Exhibit 07: Diabetes in people aged 20-79 years in Europe 2013 and 2035
Exhibit 08: Proportion of diabetes in top countries of Europe 2013 (millions)
Exhibit 09: Diabetes in Europe among people aged 20-79 years by gender 2014
Exhibit 10: Approved product portfolio
Exhibit 11: Pipeline portfolio: Insulin market in US and Europe
Exhibit 12: Share of pipeline products in insulin market in US and Europe by stage of development 2015
Exhibit 13: Pipeline share of top companies in insulin market in US and Europe
Exhibit 14: Oramed Pharmaceuticals: Pipeline products
Exhibit 15: Global insulin market 2015-2020 ($ billions)
Exhibit 16: Market share of global insulin drugs in global pharmaceutical market 2015
Exhibit 17: Global insulin market in the US and Europe 2015-2020 ($ billions)
Exhibit 18: Five forces analysis
Exhibit 19: Segmentation of insulin market in US and Europe by drug class
Exhibit 20: Market share of insulin in US and Europe by drug class
Exhibit 21: Marketed insulin formulations
Exhibit 22: Insulin market in US and Europe by application 2015
Exhibit 23: Insulin delivery technologies
Exhibit 24: Insulin pumps market in US 2015-2020 ($ millions)
Exhibit 25: Insulin pumps market in Europe 2015-2020 ($ millions)
Exhibit 26: Geographical segmentation of insulin market in US and Europe 2015
Exhibit 27: Insulin market in US 2015-2020 ($ billions)
Exhibit 28: Market share of insulin in US by drug class 2015
Exhibit 29: Insulin market in Europe 2015-2020 ($ billions)
Exhibit 30: Market share of insulin in Europe by drug class 2015
Exhibit 31: Unmet medical needs in insulin market in US and Europe
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Market share analysis 2015
Exhibit 35: Revenue share of major companies for insulin market in US and Europe 2015
Exhibit 36: Revenues from the sales of top five products in insulin market in US and Europe 2013-2015 ($ billions)
Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
Exhibit 38: Sanofi: Geographical segmentation of Lantus 2015
Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
Exhibit 40: Sanofi: Geographical segmentation of Apidra 2015
Exhibit 41: Sanofi: Geographical segmentation of Toujeo 2015
Exhibit 42: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
Exhibit 43: Sanofi: Geographical segmentation of Insuman 2015
Exhibit 44: Sanofi: Key takeaways
Exhibit 45: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
Exhibit 46: Novo Nordisk: Geographical segmentation of revenues of NovoLog 2015
Exhibit 47: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
Exhibit 48: Novo Nordisk: Geographical segmentation of revenues of NovoMix 2015
Exhibit 49: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
Exhibit 50: Geographical segmentation of Levemir 2015
Exhibit 51: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
Exhibit 52: Geographical segmentation of human insulins 2015
Exhibit 53: Novo Nordisk: Key takeaways
Exhibit 54: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
Exhibit 55: Eli Lilly: Geographical segmentation of Humalog 2015
Exhibit 56: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
Exhibit 57: Eli Lilly: Geographical segmentation of Humalog 2015
Exhibit 58: Eli Lilly: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Adocia
  • Boehringer Ingelheim
  • Exsulin
  • Macrogenics
  • NGM Biopharmaceuticals
  • Pfizer
  • MORE
New Report Released: – Insulin Market in the US and Europe 2016-2020

The author of the report recognizes the following companies as the key players in the Insulin Market in the US and Europe: Sanofi, Novo Nordisk, and Eli Lilly.

Other Prominent Vendors in the market are: Adocia, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Dance Biopharm, Diasome Pharmaceuticals, Exsulin, Generex, Lexicon Pharmaceuticals, Ligand, MannKind, Macrogenics, Merck, Melior Pharmaceuticals, Metabolic Solutions Development Company, NGM Biopharmaceuticals, NuSirt Biopharma, Oramed Pharmaceuticals, PhaseBio Pharmaceuticals, Pfizer, Thermalin Diabetes, Tolerion, VeroScience, vTV Therapeutics, Wockhardt, and XOMA.

Commenting on the report, an analyst from the research team said: “A trend to note is the rising prices of insulin drugs. Apart from safety and efficacy, the cost of therapy plays a major role in deciding the number of consumers. The cost-effectiveness of a treatment needs to be analyzed while prescribing a therapy. However, due to the lack of alternative therapies, drugs like insulin are the standard treatment options despite their high cost. The insulin market in the US and Europe is expected to grow based on the rising prices of insulin analogs.”

According to the report, a key growth driver is the advances in insulin delivery technology. The development of innovative insulin products and advances in insulin delivery technology have increased the life expectancy of individuals with diabetes. Automated injection devices such as insulin pumps and pens offers a safe and easy drug delivery option, increasing their demand in the market. For instance, NovoPen and FlexTouch by Novo Nordisk are the latest developments in durable insulin delivery devices.

Further, the report states that one challenge that could have an adverse impact on market growth is the complexity of the insulin production process.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Sanofi
- Novo Nordisk
- Eli Lilly
- Adocia
- Biocon
- Biodel
- Biogenomics
- Boehringer Ingelheim
- Dance Biopharm
- Diasome Pharmaceuticals
- Exsulin
- Generex
- Lexicon Pharmaceuticals
- Ligand
- MannKind
- Macrogenics
- Merck
- Melior Pharmaceuticals
- Metabolic Solutions Development Company
- NGM Biopharmaceuticals
- NuSirt Biopharma
- Oramed Pharmaceuticals
- PhaseBio Pharmaceuticals
- Pfizer
- Thermalin Diabetes
- Tolerion
- VeroScience
- vTV Therapeutics
- Wockhardt
- XOMA.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll